gap between thiotepa and stem cell infusion
Reading File
Finding Sources
Searching PubMed
thiotepa conditioning stem cell transplant infusion interval
Finding Sources
Searching the Web
thiotepa to stem cell infusion gap hours days conditioning regimen HSCT
Searching the Web
thiotepa half-life clearance 72 hours stem cell infusion day 0 conditioning schedule
Here is a clear, evidence-based answer on the gap between thiotepa and stem cell infusion in HSCT conditioning.
Gap Between Thiotepa and Stem Cell Infusion
The Standard Gap: ~72 hours (minimum ~48 hours)
In practice, most conditioning regimens place thiotepa on Day -6 to Day -4 and schedule stem cell infusion on Day 0, creating a gap of 4 to 6 days from the start of thiotepa, and typically at least 48-72 hours from the last thiotepa dose to infusion.
The rationale is pharmacokinetic: if viable stem cells are infused while thiotepa or its active metabolite TEPA is still present in circulation, the alkylating agent will damage or kill the graft.
Thiotepa Pharmacokinetics (Why 72 Hours Works)
| Parameter | Thiotepa | TEPA (active metabolite) |
|---|---|---|
| Half-life (adults) | 1.4 - 3.7 hours | 4.9 - 17.6 hours |
| Half-life (pediatrics) | ~1.7 hours | ~4 hours |
| Urinary excretion | <2% of dose | <11% of dose |
| Metabolism | CYP3A4, CYP2B6 (hepatic) | - |
With a terminal half-life of up to ~3.7 hours for thiotepa and up to ~17.6 hours for TEPA in adults, approximately 5 half-lives (roughly 24-90 hours) is needed for adequate clearance. A gap of 72+ hours after the last thiotepa dose provides a wide safety margin for TEPA clearance before Day 0 infusion.
Typical Scheduling Patterns in Major Protocols
Beta-thalassemia (FDA-approved Tepadina regimen):
- Day -6: Thiotepa 5 mg/kg x2 doses (12 hours apart)
- Day -5 to -2: Cyclophosphamide
- Day 0: Stem cell infusion → gap = ~6 days from thiotepa
CNS Lymphoma (Carmustine + Thiotepa autologous):
- Day -6: Carmustine
- Day -5 and Day -4: Thiotepa 5 mg/kg twice daily
- Day 0: Stem cell infusion → gap = ~4 days from last thiotepa dose (from the eviQ protocol)
Thiotepa-Fludarabine-Busulfan (BFT) regimen (allogeneic):
- Day -7: Thiotepa 5 mg/kg x1 or 2 doses
- Day -6 to -3: Fludarabine + Busulfan
- Day 0: Stem cell infusion → gap = ~7 days from thiotepa
Age-adjusted PTCL regimen (Corradini):
- Day -6: Thiotepa (dose varies by age: 1, 2, or 3 doses)
- Day -4 to -3: Cyclophosphamide + Fludarabine
- Day 0: Stem cell infusion → gap = ~6 days
Key Practical Points
- Minimum safe gap is ~48-72 hours from the last thiotepa dose to stem cell infusion, based on TEPA clearance kinetics (up to 5-6 half-lives of TEPA needed).
- Most protocols use Day -6 to Day -4 for thiotepa with Day 0 infusion, giving a 4-6 day gap - well beyond the pharmacokinetic minimum.
- CYP2B6 interaction warning: If cyclophosphamide is used in the same regimen, it must be administered before thiotepa (thiotepa inhibits CYP2B6 and would otherwise impair cyclophosphamide activation).
- Day -1 is typically left as a "rest day" (no chemotherapy) before the Day 0 infusion in most regimens.
- In protocols where thiotepa is given as late as Day -4 (e.g., the CNS lymphoma carmustine/thiotepa regimen), the minimum gap to Day 0 is still 4 days (96 hours), which is sufficient given TEPA's longest half-life of ~17.6 hours.
Bottom line: The gap is at minimum 48-72 hours from the last thiotepa dose, and in clinical practice most protocols build in a 4-6 day gap (thiotepa on Day -6 to -4, infusion on Day 0), ensuring both thiotepa and TEPA are adequately cleared before viable stem cells are infused.
This is a shared conversation. Sign in to Orris to start your own chat.